Taiho signs deal to acquire Cullinan Pearl for up to $405m
On Taiho acquiring Cullinan Pearl, Cullinan Oncology is entitled to receive $275m in upfront payment.

On Taiho acquiring Cullinan Pearl, Cullinan Oncology is entitled to receive $275m in upfront payment.
Under the deal, BMS will make upfront and milestone payments of up to $905m to BridgeBio.
Astellas will handle the development, production and marketing of any licenced products developed out of the partnership.
The research project was conducted in partnership with the universities of Surrey, Leeds and Texas, as well as HOX Therapeutics.
The EC approval is based on the international Phase II ELARA clinical trial of Kymriah.
The US FDA has rejected a new drug application (NDA) from HUTCHMED for surufatinib for advanced neuroendocrine tumours (NETs).
ByTislelizumab has been making strides towards approval for the treatment of second-line oesophagal squamous cell carcinoma (ESCC).
ByAlthough some countries are moving ahead, the use of CAR-T therapies in the region remains uneven.
By